A new early trial indicates that genetically engineered cells maybe effective to compact non-Hodgkin lymphoma when combined with chemotherapy. According to the experimental study, white blood cells (T-cells) "are removed from the patient's bloodstream [and] genetically modified so hey can detected and attack cancerous B-cells." In 32 patients that underwent this treatment in this trial, 1/3 were in complete remission from non-Hodgkin lymphoma.
To read more about this trial, click here.
No comments:
Post a Comment